STLN Starling Oncology, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%
Returns
ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x
Leverage & solvency
Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $502.73M | $393.41M | $324.24M | $252.48M | $203.00M |
| SG&A expense | $105.57M | $107.83M | $113.85M | $119.69M | $83.36M |
| Operating income | -$36.08M | -$60.12M | -$77.02M | -$81.95M | -$45.86M |
| Interest expense | $11.28M | $7.50M | $6.78M | — | $320,000 |
| Pretax income | -$60.74M | -$64.66M | -$83.10M | -$91,000 | -$11.60M |
| Income tax | -$131,000 | $0 | -$36,000 | -$243,000 | -$671,000 |
| Net income | -$60.61M | -$64.66M | -$83.07M | $152,000 | -$10.93M |
| EBITDA | -$29.14M | -$53.83M | -$71.14M | -$77.54M | -$42.52M |
| EPS (basic) | -0.54 | -0.71 | -0.92 | 0.00 | -0.16 |
| EPS (diluted) | -0.54 | -0.71 | -0.92 | -0.21 | -0.16 |
| Weighted avg. shares (diluted) | 92.39M | 75.04M | 73.75M | 80.61M | 66.23M |
| Banking | |||||
| Net interest income | — | — | -$6.78M | -$4.08M | -$320,000 |
| Balance sheet | |||||
| Cash & equivalents | $33.56M | $49.67M | $33.49M | $14.01M | $115.17M |
| Short-term investments | — | $0 | $49.37M | $59.80M | $0 |
| Receivables | $59.00M | $48.34M | $42.36M | $39.82M | $20.01M |
| Inventory | $16.88M | $10.04M | $13.68M | $9.26M | $6.44M |
| Current assets | $112.75M | $112.42M | $143.49M | $130.42M | $154.06M |
| PP&E, net | $10.68M | $11.89M | $10.88M | $8.55M | $4.19M |
| Goodwill | $7.23M | $7.23M | $7.23M | $21.42M | $26.63M |
| Intangibles | $11.02M | $14.81M | $17.90M | $17.96M | $18.25M |
| Total assets | $164.66M | $172.72M | $209.24M | $261.67M | $203.44M |
| Current liabilities | $70.96M | $52.22M | $34.79M | $29.72M | $29.80M |
| Short-term debt | — | — | — | $0 | $183,000 |
| Long-term debt | $77.40M | $93.13M | $86.83M | $80.62M | $0 |
| Total debt | $77.40M | $93.13M | $86.83M | $80.62M | $183,000 |
| Total liabilities | $180.38M | $169.13M | $152.22M | $138.49M | $99.28M |
| Shareholders' equity | -$15.72M | $3.59M | $57.02M | $123.17M | $104.16M |
| Net debt | $43.84M | $43.46M | $53.34M | $66.61M | -$114.99M |
| Shares outstanding | 98.86M | 75.74M | 74.15M | 73.27M | 73.25M |
| Cash flow statement | |||||
| Operating cash flow | -$24.59M | -$26.54M | -$36.31M | -$61.76M | -$32.68M |
| Capital expenditure | $3.20M | $3.79M | $4.57M | $5.53M | $2.85M |
| Free cash flow | -$27.79M | -$30.33M | -$40.88M | -$67.28M | -$35.53M |
| Investing cash flow | -$3.07M | $46.21M | $62.64M | -$131.61M | -$12.15M |
| Financing cash flow | $11.56M | -$3.49M | -$6.85M | $92.21M | $154.01M |
| Depreciation & amortization | $6.94M | $6.29M | $5.87M | $4.41M | $3.34M |
| Stock-based compensation | $4.55M | $11.15M | $17.81M | $27.68M | $24.54M |
| Share buybacks | — | $0 | $1.02M | $9.00M | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.